3-(1,1,2,3,3,3-六氟丙基)金刚烷-1-羧酸 | 86301-98-6

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 3-(1,1,2,3,3,3-六氟丙基)金刚烷-1-羧酸
• 英文名称: 3-(1,1,2,3,3,3-hexafluoropropyl)adamantan-1-carboxylic acid
• 英文别名: 3-(1,1,2,3,3,3-Hexafluoropropyl)adamantane-1-carboxylic acid
• CAS: 86301-98-6
• 化学式: C₁₄H₁₆F₆O₂
• mdl: MFCD00193108
• 分子量: 330.27
• InChiKey: GLJDZZQQPFAEPQ-UHFFFAOYSA-N

物化性质

• 熔点：
  115 °C
• 沸点：
  326.9±37.0 °C(Predicted)
• 密度：
  1.474±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  22
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.928
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  8

安全信息

• 危险品标志：
  Xi
• 安全说明：
  S26,S37/39
• 危险类别码：
  R36/37/38

SDS

Name:	3-(1 1 2 3 3 3-Hexafluoropropyl)adamantane-1-carboxylic acid 97% Material Safety Data Sheet
Synonym:
CAS:	86301-98-6

Section 1 - Chemical Product MSDS Name:3-(1 1 2 3 3 3-Hexafluoropropyl)adamantane-1-carboxylic acid 97% Material Safety Data Sheet
Synonym:

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
86301-98-6	3-(1,1,2,3,3,3-Hexafluoropropyl)adaman	97%	unlisted

Hazard Symbols: XI
Risk Phrases: 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Irritating to eyes, respiratory system and skin.
Potential Health Effects
Eye:
Causes eye irritation.
Skin:
Causes skin irritation. May be harmful if absorbed through the skin.
Ingestion:
May cause irritation of the digestive tract. May be harmful if swallowed.
Inhalation:
Causes respiratory tract irritation. May be harmful if inhaled.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Absorb spill with inert material (e.g. vermiculite, sand or earth), then place in suitable container. Vacuum or sweep up material and place into a suitable disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 86301-98-6: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: white
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 115 - 117 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C14H16F6O2
Molecular Weight: 330

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Oxidizing agents.
Hazardous Decomposition Products:
Carbon monoxide, carbon dioxide, acrid smoke and fumes, fluorine, hydrogen fluoride gas.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 86301-98-6 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
3-(1,1,2,3,3,3-Hexafluoropropyl)adamantane-1-carboxylic acid - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
No information available.
IMO
No information available.
RID/ADR
No information available.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XI
Risk Phrases:
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 37/39 Wear suitable gloves and eye/face
protection.
WGK (Water Danger/Protection)
CAS# 86301-98-6: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 86301-98-6 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 86301-98-6 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  3-(1,1,2,3,3,3-六氟丙基)金刚烷-1-羧酸 在 氯化亚砜 作用下， 反应 1.0h， 生成 3-(1,1,2,3,3,3-Hexafluoro-propyl)-adamantane-1-carbonyl chloride
  参考文献：
  名称：

  Nazarova, M. P.; Morozov, V. A.; Podkhalyuzin, A. T., Journal of Organic Chemistry USSR (English Translation), 1983, vol. 19, p. 499 - 504

  摘要：

  DOI：
• 作为产物：
  描述：

  甲酸 、 1-溴-3-(1,1,2,3,3,3-六氟丙基)金刚烷 在 硫酸 作用下， 反应 1.0h， 以97.9%的产率得到3-(1,1,2,3,3,3-六氟丙基)金刚烷-1-羧酸
  参考文献：
  名称：

  Nazarova, M. P.; Morozov, V. A.; Podkhalyuzin, A. T., Journal of Organic Chemistry USSR (English Translation), 1983, vol. 19, p. 499 - 504

  摘要：

  DOI：

文献信息

• Acylhydrazine P2X7 antagonists and uses thereof
  申请人：Nelson W. Derek

  公开号：US20060276505A1

  公开（公告）日：2006-12-07

  The present invention discloses a compound of formula (I) or a pharmaceutically acceptable salt or prodrug thereof, wherein D, A, m, n, R x and R y are defined in the description. The present invention also relates to pharmaceutical compositions of compounds of formula (I), which are useful for treating a disorder selected from the group consisting of chronic inflammatory pain, neuropathic pain, inflammation, neurodegeneration, depression and promoting neuroregeneration. The present invention also relates to a method for treating pain, neuropathic pain, inflammation, chronic inflammatory pain, neurodegeneration, depression and promoting neuroregeneration in a mammal using compounds of formula (II), a pharmaceutically acceptable salt, ester, amide or prodrug thereof, wherein R 3 and R 4 are defined in the description.

  本发明揭示了一种式（I）的化合物或其药学上可接受的盐或前药，其中D，A，m，n，Rx和Ry在说明中定义。本发明还涉及式（I）化合物的药物组合物，其用于治疗选择自慢性炎性疼痛、神经病理性疼痛、炎症、神经退行性疾病、抑郁症和促进神经再生的疾病。本发明还涉及一种使用式（II）化合物、其药学上可接受的盐、酯、酰胺或前药治疗哺乳动物的疼痛、神经病理性疼痛、炎症、慢性炎性疼痛、神经退行性疾病、抑郁症和促进神经再生的方法，其中R3和R4在说明中定义。
• Novel Pyridylmethylamines as Highly Selective 5-HT_1A Superagonists
  作者：Stefan Bollinger、Harald Hübner、Frank W. Heinemann、Karsten Meyer、Peter Gmeiner

  DOI：10.1021/jm100835q

  日期：2010.10.14

  To further improve the maximal serotonergic efficacy and better understand the configurational requirements for 5-HT1A binding and activation, we generated and biologically investigated structural variants of the lead structure befiradol. For a bioisosteric replacement of the 3-chloro-4-fluoro moiety, a focused library of 63 compounds by solution phase parallel synthesis was developed. Target binding of our compound collection was investigated, and their affinities for 5-HT2, alpha(1), and alpha(2)-adrenergic as well as D-1-D-4 at dopamine receptors were compared. For particularly interesting test compounds, intrinsic activities at 5-HT1A were examined in vitro employing a GTP gamma S assay. The investigation guided as to highly selective 5HT(1A) superagonists. The benzothiophene-3-carboxamide 8bt revealed almost exclusive 5HT(1A) recognition with a K-i value of 2.7 nM and a maximal efficacy of 124%. To get insights into the bioactive conformation of our compound collection, we synthesized conformationally constrained bicyclic scaffolds when SAR data indicated a chair-type geometry and an equatorially dispositioned aminomethyl substituent for the 4,4-disubstituted piperidine moiety.
• NAZAROVA, M. P.;MOROZOV, V. A.;PODXALYUZIN, A. T., ZH. ORGAN. XIMII, 1983, 19, N 3, 565-571
  作者：NAZAROVA, M. P.、MOROZOV, V. A.、PODXALYUZIN, A. T.

  DOI：——

  日期：——
• Nazarova, M. P.; Morozov, V. A.; Podkhalyuzin, A. T., Journal of Organic Chemistry USSR (English Translation), 1983, vol. 19, p. 499 - 504
  作者：Nazarova, M. P.、Morozov, V. A.、Podkhalyuzin, A. T.

  DOI：——

  日期：——